NewAmsterdam Pharma (NAMS)
Develops oral obicetrapib for adjunct LDL-C lowering.
$25.60
At close+0.68 (+2.73%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions213 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 101.38% | 121.19M shares | |
| Insiders17 holders · as of Aug 25, 2026 | 23.34% | 27.91M shares | |
| Adds to | 124.72% |
119.54M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 124.72%; nothing is left for Other.
Institutions13F, as of Jun 30, 2026
213 holders · 121.19M shares · 48 new positions · 122 increased · 50 reduced · 22 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 18.09M | 15.13% | +1.15M | Aug 14, 2026 |
| Capital World Investors | 12.23M | 10.23% | +1.12M | Aug 12, 2026 |
| FMR LLC | 10.34M | 8.65% | +1.57M | Aug 13, 2026 |
| Ra Capital Management, L.P. | 9.55M | 7.99% | 0 | Aug 14, 2026 |
| FCPM Iii Services B.V. | 8.49M | 7.10% | −708.5K | Aug 14, 2026 |
| Deerfield Management Company, L.P. (Series C) | 4.26M | 3.57% | 0 | Aug 14, 2026 |
| Viking Global Investors LP | 4.20M | 3.52% | 0 | Aug 14, 2026 |
| Bain Capital Life Sciences Investors, LLC | 3.81M | 3.18% | −3.50M | Aug 14, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Capital World Investors | 10.40% | 12.19M | 13G | Jun 4, 2026 ↗ |
| RA Capital Management, L.P. | 9.90% | 11.06M | 13G | May 15, 2025 ↗ |
| ForGrowth NAP B.V.incl. Forbion Growth Opportunities Fund I Cooperatief U.A., Forbion IV Management B.V. +2 more | 8.30% | 9.32M | 13D | Sep 30, 2025 ↗ |
| FMR LLC | 7.60% | 8.77M | 13G | May 6, 2026 ↗ |
| Frazier Life Sciences X, L.P. | 6.50% | 7.33M | 13D | Nov 4, 2025 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 24, 2026 | Johannes Jacob Pieter Kasteleindirector, officer: Chief Scientific Officer | Sale | 125,000 | $26.91 | 69,302 |
| Jul 20, 2026 | Louise Frederika Kooijofficer: Chief Accounting Officer | Sale · 3 lots | 105,000 | $30.34 | 24,353 |
| Jun 22, 2026 | Louise Frederika Kooijofficer: Chief Accounting Officer | Sale · 2 lots | 40,000 | $30.20 | 24,353 |
| May 26, 2026 | Louise Frederika Kooijofficer: Chief Accounting Officer | Sale | 65,000 | $35.69 | 24,353 |
| Mar 11, 2026 | Louis G. Langedirector | Sale · 2 lots | 44,619 | $30.42 | 10,360 |
| Mar 6, 2026 | Louis G. Langedirector | Sale | 28,186 | $29.41 | 0 |
| Mar 5, 2026 | Johannes Jacob Pieter Kasteleindirector, officer: Chief Scientific Officer | Sale | 104,467 | $30.30 | 69,302 |
| Mar 9, 2026 | Johannes Jacob Pieter Kasteleindirector, officer: Chief Scientific Officer | Sale | 101,409 | $30.29 | 69,302 |
| Mar 6, 2026 | Johannes Jacob Pieter Kasteleindirector, officer: Chief Scientific Officer | Sale | 94,124 | $30.32 | 69,302 |
| Mar 2, 2026 | Michael H. Davidsondirector, officer: Chief Executive Officer | Sale | 443,707 | $33.25 | 174,144 |
CongressHouse and Senate disclosures
Not reported.